Dose response effect of conjugated equine oestrogen on blood pressure in postmenopausal women with hypertension

被引:19
作者
Harvey, PJ
Molloy, D
Upton, J
Wing, LM
机构
[1] Flinders Univ S Australia, Dept Clin Pharmacol, Adelaide, SA 5001, Australia
[2] Flinders Univ S Australia, Dept Med, Adelaide, SA 5001, Australia
基金
英国医学研究理事会;
关键词
ambulatory blood pressure; blood pressure; hypertension; menopause; oestrogen;
D O I
10.1080/080370500448669
中图分类号
R6 [外科学];
学科分类号
1002 [临床医学]; 100210 [外科学];
摘要
Objective: This study was designed to compare with placebo the dose-response of conjugated equine oestrogen (CEE) on blood pressure in hypertensive postmenopausal women. Design and Methods: Fourteen postmenopausal women with grade 1-2 hypertension participated in the study which used a double-blind crossover design. There were four randomised treatment phases, each lasting 4 weeks. The four treatments were CEE 0.3 mg, CEE 0.625 mg, CEE 1.25 mg and placebo. Each subject also received non-blinded medroxyprogesterone acetate (MPA) 10 mg for the final 14 days of each 28-day treatment cycle. Clinic blood pressure was measured weekly with the mean values of weeks 3 and 4 of each phase used for analysis. Ambulatory blood pressure was performed in week 4 of each phase. Results: Compared with placebo, clinic systolic blood pressure was reduced in the CEE 0.3 mg and CEE 0.625 mg phases (p < 0.05) and clinic diastolic blood pressure was reduced in the CEE 0.625 mg phase (p < 0.05). There was no significant effect of CEE on ambulatory blood pressure, although the blood pressure pattern was similar to clinic measurements. Conclusion: In hypertensive postmenopausal women, daily CEE together with cyclical MPA has a variable effect on blood pressure depending on CEE dose. The "lower" and "middle" doses of CEE produced a small reduction in blood pressure which reached a nadir and tended to reverse with the "higher" CEE dose.
引用
收藏
页码:275 / 282
页数:8
相关论文
共 54 条
[1]
AKAHOSHI M, 1994, J HYPERTENS, V12, pS74
[2]
[Anonymous], 1991, JAMA, V265, P3255
[3]
ARMITAGE P, 1994, STAT METHODS MED RES, P448
[4]
MENOPAUSE-RELATED CHANGES IN LIPOPROTEINS AND SOME OTHER CARDIOVASCULAR RISK-FACTORS [J].
BONITHONKOPP, C ;
SCARABIN, PY ;
DARNE, B ;
MALMEJAC, A ;
GUIZE, L .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 1990, 19 (01) :42-48
[5]
HYPERTENSION DUE TO A RENIN-SECRETING TUMOR LOCALIZED BY SEGMENTAL RENAL-VEIN SAMPLING [J].
BONNIN, JM ;
CAIN, MD ;
JOSE, JS ;
MUKHERJEE, TM ;
PERRETT, LV ;
SCROOP, GC ;
SEYMOUR, AE .
AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1977, 7 (06) :630-635
[6]
Casiglia E, 1996, J HYPERTENS, V14, P729
[7]
Chalmers J, 1999, J HYPERTENS, V17, P151
[8]
CHANG WC, 1980, BIOCHIM BIOPHYS ACTA, V619, P107
[9]
EFFECTS OF NATURAL ESTROGEN-GESTAGEN AND THIAZIDE ON CORONARY RISK-FACTORS IN NORMAL POST-MENOPAUSAL WOMEN - A 2-YEAR DOUBLE-BLIND PLACEBO STUDY [J].
CHRISTIANSEN, C ;
CHRISTENSEN, MS ;
HAGEN, C ;
STOCKLUND, KE ;
TRANSBOL, I .
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 1981, 60 (04) :407-412
[10]
NITRIC-OXIDE ACCOUNTS FOR DOSE-DEPENDENT ESTROGEN-MEDIATED CORONARY RELAXATION AFTER ACUTE ESTROGEN WITHDRAWAL [J].
COLLINS, P ;
SHAY, J ;
JIANG, CW ;
MOSS, J .
CIRCULATION, 1994, 90 (04) :1964-1968